Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Impact of PLND on oncologic outcomes after radical prostatectomy in men with prostate cancer

Key clinical point: In men with prostate cancer (PCa) who underwent nodal dissection at radical prostatectomy (RP), more extensive pelvic lymph node dissection (PLND) was not associated with improved oncologic outcomes.

Major finding: Seven-year biochemical recurrence‐free survival (bRFS), overall survival (OS), and PCa‐specific mortality were similar with 14 or more vs. less than 14 lymph nodes dissected (P less than .05 for all). Among node-positive patients, 7‐year bRFS differed (75% for undetectable [UDT] prostate-specific antigen [PSA], 90% for UDT + adjuvant therapy, and 38% for detectable PSA), but OS was similar between these groups.

Study details: The data come from a cohort study of 1,543 men who underwent primary RP with PLND for PCa.

Disclosures: The study was supported by the UCSF Goldberg‐Benioff Program in Cancer Translational Biology. The authors declared no conflicts of interest.


Washington SL 3rd et al. Prostate. 2020 Oct 19. doi: 10.1002/pros.24085.